Pathogenesis, lethality, and immunizing effect of experimental cutaneous cryptococcosis.
Mice were subcutaneously inoculated with small numbers of virulent Cryptococcus neoformans and divided into groups. Numbers of viable yeasts at the site were estimated at weekly intervals for 5 weeks on the basis of cultures of minced tissue excised from sacrificed animals. Organisms multiplied at the site for at least 4 weeks and were still detectable after the 5th week, although in reduced numbers. Agglutinins appeared within a week, but these antibodies were not detectable during the 2nd through the 5th week. Cryptococcal polysaccharide began to appear in the sera at 3 weeks, persisting through the duration of 5 weeks. All animals appeared healthy, but a few sickened after many months and died of systemic cryptococcosis. All of these events were observed in many separate experiments. The immunizing capacity of a cutaneous lesion was tested by challenging some of the above animals with viable C. neoformans after various intervals of time, either subcutaneously at a site distant from that of the vaccination or intravenously. Although we were unable to demonstrate reduced multiplication of yeasts in the brains, lungs, and spleens of intravenously challenged animals, it was possible to show that multiplication was inhibited at the site of subcutaneous challenge. It was noted also that vaccinated animals lived longer after lethal intravenous challenge than did nonvaccinated animals. The latter protection was observed, however, only when challenge followed vaccination by 3 weeks or longer, and it was effective only against a relatively low challenge dose. Mice were protected against a higher dose if they had previously received killed cryptococci, alternating subcutaneous and intraperitoneal inoculations, one of which contained a microbial adjuvant. No protection was observed in animals that were subcutaneously vaccinated with inert materials such as chitin, latex spheres, or even cryptococcal cell walls themselves.
D000276:Adjuvants, Immunologic; D000818:Animals; D000908:Antibodies, Fungal / Q000032:analysis; D003453:Cryptococcosis / Q000276:immunology / Q000517:prevention & control*; D003455:Cryptococcus neoformans / Q000254:growth & development / Q000276:immunology; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007156:Immunologic Memory; D007249:Inflammation / Q000276:immunology; D051379:Mice; D013997:Time Factors; D014611:Vaccination
D000276:Adjuvants, Immunologic; D000908:Antibodies, Fungal